CNV-2197944

N/A

Report date: 2022/07/19 20:00:45
NME

Base Information

Drug NameCNV-2197944
Drug Alias NameCNV-2197944
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionVoltage-gated N-type calcium channel alpha-1B subunit blockers
TargetsVoltage-gated N-type calcium channel alpha-1B subunit
Therapy Area/IndicationsDiabetic peripheral neuropathyNeuralgia, Postherpetic
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySouth AfricaHungary
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesGlaxosmithkline PlcBiogen Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesConvergence Pharmaceuticals
Active IndicationsN/A
Inactive IndicationsDiabetic peripheral neuropathyNeuralgia, Postherpetic

Other Information

ATC CodeN/A
Related LinksN/A